First sickle cell patient was dosed Oct 14, and the Bluebird should know if the patient is transfusion independent in less than two weeks - plenty of time for an ASH report. While guidance is for 2015, there may be an early surprise?
With another round of data in the coming months, BCLI stands a reasonable chanced for an expanded access program. Results for this program are rapid and interim data may be available following the 3 month endpoint measurement. The first site came online in June. Without surgery, this program can rapidly enroll patients and measure outcomes - far different than Neuralstem. To date there have been few side effects.